Massachusetts Financial Services Co. MA lowered its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 3.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 79,563 shares of the biopharmaceutical company’s stock after selling 3,049 shares during the period. Massachusetts Financial Services Co. MA owned about 0.07% of Catalyst Pharmaceuticals worth $930,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in CPRX. Advisory Services Network LLC boosted its stake in Catalyst Pharmaceuticals by 260.2% in the 1st quarter. Advisory Services Network LLC now owns 1,801 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 1,301 shares during the period. VisionPoint Advisory Group LLC acquired a new position in Catalyst Pharmaceuticals in the 2nd quarter worth $43,000. FMR LLC boosted its stake in Catalyst Pharmaceuticals by 24.2% in the 2nd quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 822 shares during the period. Covestor Ltd boosted its stake in Catalyst Pharmaceuticals by 768.0% in the 1st quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 4,316 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Catalyst Pharmaceuticals in the 1st quarter worth $62,000. Institutional investors own 77.27% of the company’s stock.
Catalyst Pharmaceuticals Price Performance
Shares of CPRX stock opened at $13.64 on Tuesday. The firm has a 50 day moving average price of $14.87 and a two-hundred day moving average price of $13.86. The company has a market capitalization of $1.60 billion, a PE ratio of 26.23 and a beta of 0.93. Catalyst Pharmaceuticals, Inc. has a 12-month low of $11.09 and a 12-month high of $18.22.
Insiders Place Their Bets
Wall Street Analyst Weigh In
CPRX has been the subject of a number of research analyst reports. TheStreet lowered shares of Catalyst Pharmaceuticals from a “b” rating to a “c+” rating in a research note on Thursday, November 9th. Oppenheimer began coverage on Catalyst Pharmaceuticals in a report on Thursday, December 21st. They issued an “outperform” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.80.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
- Five stocks we like better than Catalyst Pharmaceuticals
- How Can Investors Benefit From After-Hours Trading
- 3 attractive stocks that insiders are buying
- What Are MATANA Stocks?
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Insider Trades May Not Tell You What You Think
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.